Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.165 USD | +0.70% | -11.02% | -34.53% |
Mar. 20 | HC Wainwright Adjusts Coherus BioSciences' Price Target to $11 From $13, Keeps Buy Rating | MT |
Mar. 14 | Coherus BioSciences Shares Fall After Workforce Reduction Plan; Q4 Loss | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-34.53% | 244M | C- | ||
-3.29% | 102B | B+ | ||
+3.17% | 96.09B | B+ | ||
-1.02% | 22.05B | B | ||
-18.11% | 20.81B | B+ | ||
-6.87% | 19.06B | A- | ||
-40.70% | 16.05B | A- | ||
-26.29% | 14.01B | B | ||
+1.71% | 13.38B | C+ | ||
+22.48% | 11.01B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CHRS Stock
- Ratings Coherus BioSciences, Inc.